Industry Partnerships
Biomedical Advanced Research and Development Agency (BARDA)
Vedanta has been awarded a development grant from BARDA to advance VE303 through clinical and regulatory development for CDI. The contract provides for reimbursement of up to $104.2 million, subject to additional prespecified milestones being achieved and the availability of funding. BARDA has exercised its first option under this partnership to support a Phase 3 clinical trial of VE303.
CARB-X
Vedanta has been awarded two research grants from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) to support the development of VE303, the Company’s product candidate for the treatment of high-risk C. difficile infection (CDI), and VE707, Vedanta’s preclinical discovery program for the prevention of infection and recurrence of several MDROs, including carbapenem-resistant Enterobacteriaceae (CRE), extended-spectrum beta lactamase producers (ESBL), and vancomycin-resistant Enterococci (VRE).
Academic Collaborations
Leiden University Medical Center
We have entered into a clinical translational medicine collaboration with Leiden University Medical Center that focuses on collection of samples from healthy donors as well as clinical data and/or interventional studies of fecal transplantation in a variety of indications.